{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T07:02:10Z","timestamp":1779778930966,"version":"3.53.1"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Postural Orthostatic Tachycardia Syndrome (POTS) is notoriously difficult to diagnose and successfully treat. POTS encompasses several different subtypes, but little research attention has focused on optimizing the diagnosis and treatment of specific subtypes. This study aims to identify variables potentially predictive of neuropathic POTS and determine which current medical therapies for POTS are most successful in the neuropathic population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Single-center retrospective review identified 382 patients diagnosed with POTS between 2018 and 2020. Diagnosis was established via the head-up tilt table test; neuropathic subtype was established via skin biopsy or quantitative sudomotor axon reflex test. Logistic regression identified variables predictive of the neuropathic subtype; Cox proportional hazard and Kaplan-Meier estimator modeling were employed to compare treatment response to medications between neuropathic and non-neuropathic patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Patients with neuropathic POTS treated with ivabradine exhibited a median treatment response duration of 26.7 months in the neuropathic group vs. 10.7 months in the non-neuropathic group, reflecting a significantly reduced risk of treatment failure (hazard ratio = 0.273,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.028). No other studied treatments demonstrated different response. Of the clinical and demographic variables studied, only elevated baseline heart rate was significantly associated with the neuropathic POTS subtype, though with questionable clinical significance.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Patients with neuropathic POTS may exhibit different medication treatment response compared to patients with non-neuropathic POTS, though prospective studies are needed for confirmation. Further study to identify optimal treatment regimens for different subtypes of POTS is a promising direction to improve the quality of care for patients with POTS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2026.1796563","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T06:02:47Z","timestamp":1779775367000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Maximizing treatment response in patients with neuropathic-subtype postural orthostatic tachycardia syndrome"],"prefix":"10.3389","volume":"17","author":[{"given":"Ryan G.","family":"Rilinger","sequence":"first","affiliation":[{"name":"Cleveland Clinic Lerner College of Medicine","place":["Cleveland, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeline Y.","family":"Chin","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Lerner College of Medicine","place":["Cleveland, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Cantrell","sequence":"additional","affiliation":[{"name":"Department of Neurology, Cleveland Clinic Foundation","place":["Cleveland, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mackaleigh","family":"Levine","sequence":"additional","affiliation":[{"name":"Department of Neuromuscular Medicine, Cleveland Clinic Foundation","place":["Cleveland, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha J.","family":"Stallkamp Tidd","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Rochester Medical Center","place":["Rochester, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wilson","sequence":"additional","affiliation":[{"name":"Department of Neuromuscular Medicine, Cleveland Clinic Foundation","place":["Cleveland, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/joim.12895","article-title":"The face of postural tachycardia syndrome - insights from a large cross-sectional online community-based survey","volume":"286","author":"Shaw","year":"2019","journal-title":"J Intern Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1411960","DOI":"10.3389\/fneur.2024.1411960","article-title":"Factors associated with initiation of pharmacological therapy and treatment changes in postural orthostatic tachycardia syndrome","volume":"15","author":"Stallkamp-Tidd","year":"2024","journal-title":"Front Neurol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1146\/annurev-med-041818-011630","article-title":"Postural orthostatic tachycardia syndrome: mechanisms and new therapies","volume":"71","author":"Mar","year":"2020","journal-title":"Annu Rev Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41598-023-50886-8","article-title":"Symptom presentation by phenotype of postural orthostatic tachycardia syndrome","volume":"14","author":"Angeli","year":"2024","journal-title":"Sci Rep."},{"key":"B5","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.jacc.2020.12.029","article-title":"Randomized trial of ivabradine in patients with hyperadrenergic postural orthostatic tachycardia syndrome","volume":"77","author":"Taub","year":"2021","journal-title":"J Am Coll Cardiol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1042\/CS20130222","article-title":"A double-blind placebo-controlled cross-over study of the vascular effects of midodrine in neuropathic compared with hyperadrenergic postural tachycardia syndrome","volume":"126","author":"Ross","year":"2014","journal-title":"Clin Sci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"342","DOI":"10.3389\/fneur.2020.00342","article-title":"Which method for diagnosing small fiber neuropathy?","volume":"11","author":"Fabry","year":"2020","journal-title":"Front Neurol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e84716","DOI":"10.1371\/journal.pone.0084716","article-title":"Structural and functional small fiber abnormalities in the neuropathic postural tachycardia syndrome","volume":"8","author":"Gibbons","year":"2013","journal-title":"PLoS ONE."},{"key":"B9","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1212\/CPJ.0000000000000770","article-title":"Quantitative sensory testing predicts histological small fiber neuropathy in postural tachycardia syndrome","volume":"10","author":"Billig","year":"2020","journal-title":"Neurol Clin Pract."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e033485","DOI":"10.1161\/JAHA.123.033485","article-title":"Long-term POTS outcomes survey: diagnosis, therapy, and clinical outcomes","volume":"13","author":"Boris","year":"2024","journal-title":"J Am Heart Assoc."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1080\/13543784.2022.2121697","article-title":"Postural orthostatic tachycardia syndrome: pathophysiology, management, and experimental therapies","volume":"31","author":"Narasimhan","year":"2022","journal-title":"Expert Opin Investig Drugs."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1177\/0883073820948679","article-title":"Treatment of postural orthostatic tachycardia syndrome with medication: a systematic review","volume":"35","author":"Hasan","year":"2020","journal-title":"J Child Neurol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"E378","DOI":"10.1503\/cmaj.211373","article-title":"Diagnosis and management of postural orthostatic tachycardia syndrome","volume":"194","author":"Raj","year":"2022","journal-title":"CMAJ."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1016\/j.hrthm.2015.03.029","article-title":"2015 heart rhythm society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope","volume":"12","author":"Sheldon","year":"2015","journal-title":"Heart Rhythm."},{"key":"B15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.autneu.2018.04.004","article-title":"Evaluation of postural tachycardia syndrome (POTS)","volume":"215","author":"Goodman","year":"2018","journal-title":"Auton Neurosci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e31021","DOI":"10.7759\/cureus.31021","article-title":"Skin biopsy and quantitative sudomotor axon reflex testing in patients with postural orthostatic tachycardia syndrome","volume":"14","author":"Zhang","year":"2022","journal-title":"Cureus."},{"key":"B17","doi-asserted-by":"publisher","first-page":"P1","DOI":"10.1212\/WNL.84.14_supplement.P1.282","article-title":"Normative values for Sudomotor Axon Reflex testing using QSWEATTM (P1","volume":"84","author":"Sletten","year":"2015","journal-title":"Neurology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1002\/mus.23971","article-title":"Sural sensory nerve action potential, epidermal nerve fiber density, and quantitative sudomotor axon reflex in the healthy elderly","volume":"49","author":"Tavee","year":"2014","journal-title":"Muscle Nerve."},{"key":"B19","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jclinepi.2015.08.038","article-title":"PROMIS\u00ae measures of pain, fatigue, negative affect, physical function, and social function demonstrate clinical validity across a range of chronic conditions","volume":"73","author":"Cook","year":"2016","journal-title":"J Clin Epidemiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","article-title":"A brief measure for assessing generalized anxiety disorder: the GAD-7","volume":"166","author":"Spitzer","year":"2006","journal-title":"Arch Intern Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure","volume":"16","author":"Kroenke","year":"2001","journal-title":"J Gen Intern Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s40256-017-0252-1","article-title":"Ivabradine for the treatment of postural orthostatic tachycardia syndrome: a systematic review","volume":"18","author":"Gee","year":"2018","journal-title":"Am J Cardiovasc Drugs."},{"key":"B23","doi-asserted-by":"publisher","first-page":"3728","DOI":"10.1093\/brain\/awz333","article-title":"Diagnostic criteria for small fibre neuropathy in clinical practice and research","volume":"142","author":"Devigili","year":"2019","journal-title":"Brain."},{"key":"B24","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/mus.23891","article-title":"Contribution of QSART to the diagnosis of small fiber neuropathy","volume":"48","author":"Thaisetthawatkul","year":"2013","journal-title":"Muscle Nerve."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1796563\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T06:02:47Z","timestamp":1779775367000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1796563\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":24,"alternative-id":["10.3389\/fneur.2026.1796563"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1796563","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"article-number":"1796563"}}